산업 뉴스
제약 산업 동향과 새로운 기술에 대한 인사이트
전체 뉴스
총 59개 기사
Cancer Cell Review Links ADC Performance to Tumor Ecosystem Biology
The practical message from the Cancer Cell review is that an antibody-drug conjugate cannot be evaluated by target presence alone. An ADC must bind an antigen, reach the relevant intracellular trafficking route, release a payload in the intended compartment, and be assessed in the tumor and patient context described by the review. That makes precision ADC development a combined biology, chemistry, and analytics problem.
On-Resin Disulfide Formation in Peptide SPPS
On-resin disulfide formation builds a cysteine-cysteine bond while the peptide remains attached to a solid-phase synthesis resin. For CHEMOS readers, the practical question is whether this placement can simplify workup and control intramolecular cyclization without creating new impurity risks. The process variables are linked: oxidant choice, protecting groups, resin swelling, solvent salts, reaction time, and TFA scavenger composition can all affect the final crude peptide profile.
GalNAc-siRNA ADME: Uptake, Metabolism, and DDI Lessons
For oligonucleotides, the familiar small-molecule ADME checklist is useful as a list of questions, not as a mechanistic shortcut. These molecules are large, highly charged nucleic acid polymers that rely on non-oral delivery, uptake pathways, and nuclease-driven metabolism. For CHEMOS readers, the chemistry translation is direct: GalNAc building blocks, linker behavior, backbone modification, nuclease stability, and LC-MS method design all affect what downstream ADME data can mean.
Glycan-Directed ADC Conjugation: Donor Design and DAR Control
OBI Pharma's WO2026117757 describes a method for building site-specific antibody-drug conjugates through the conserved N297 glycan region of an antibody. The workflow trims native N-glycans to a core GlcNAc acceptor, installs functionalized sugar donors, and then couples linker-payload units by bioorthogonal chemistry. CHEMOS readers should care because the disclosure frames DAR as a glycan-donor design variable, not only as an outcome of stochastic lysine or cysteine conjugation.
Site-Specific ADC Conjugation: Chemistry Choices for DAR Control
Site-specific ADC conjugation attaches payloads at defined antibody locations instead of relying on broadly reactive lysine or reduced disulfide chemistry. Site-specific ADC strategies include engineered cysteine, unnatural amino acid, and enzymatic routes as three major ways to control drug-to-antibody ratio (DAR), commonly around 2 or 4. For CHEMOS readers, the practical issue is not only biological design but linker-payload compatibility, hydrophobicity management, reaction sequence, and LC-MS confirmation.
5'-VP Makes GalNAc-siRNA 5'-End Control a Screening Question
5'-(E)-vinylphosphonate, or 5'-VP, is a phosphate mimic placed at the 5' end of an siRNA antisense strand. In the primary ChemBioChem paper cited by the source, the reported response depended on whether a sequence was phosphate-dependent, rather than on GalNAc delivery alone. The practical question for oligonucleotide teams is when to compare 5'-OH, 5'-P, and 5'-VP versions, then track intact strand, terminal identity, total siRNA exposure, and Ago2-associated material where those assays are available.